Earnings Releases·Nov 13, 2026, 8:05 AM ET

Fortress Biotech — Q3 2026 Earnings Summary

Consolidated net revenue rose 9% year-over-year to $19.2 million, driven by a 11% increase in product revenue to $18.9 million, though the company reported a net loss of $(7.9) million compared to a $3.7 million net income in the prior year period.
Fortress repaid the full $15.0 million outstanding balance on its Oaktree senior secured credit facility in September 2026, eliminating all parent-level indebtedness and releasing associated liens.
Strategic milestones include the September 2026 approval of anselamimab in Japan for systemic kappa light chain amyloidosis, the in-licensing of FB-607 for IBS-D, and Crystalys Therapeutics closing a $130 million Series B financing.
Balance sheet strength improved significantly with cash and cash equivalents increasing to $152.2 million as of September 30, 2026, and total stockholders' equity rising to $160.0 million from $49.9 million a year earlier.
Management highlighted continued momentum for Emrosi® with approximately 40,000 total prescriptions in Q3 2026 and outlined plans to initiate clinical trials for MB-109 in the first quarter of 2027.